Glucagon-like peptide-1 analog: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
|||
| Line 6: | Line 6: | ||
==Overview== | ==Overview== | ||
'''[[Glucagon-like peptide-1]] analog'''s are a new class of [[drug]] for treatment of [[type 2 diabetes]].<ref>http://www.medscape.com/viewarticle/578304 "Glucagon-like Peptide-1 Analogs Other Than Exenatide" </ref> | '''[[Glucagon-like peptide-1]] analog'''s are a new class of [[drug]] for treatment of [[type 2 diabetes]]. <ref>http://www.medscape.com/viewarticle/578304 "Glucagon-like Peptide-1 Analogs Other Than Exenatide" </ref> One of their advantages is that they have a lower risk of causing [[hypoglycemia]]. | ||
===Licenced:=== | |||
* [[exenatide]] (2005) | |||
Under investigation : | ===Under investigation: === | ||
* albiglutide | * albiglutide | ||
Revision as of 23:15, 6 March 2009
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Please Take Over This Page and Apply to be Editor-In-Chief for this topic: There can be one or more than one Editor-In-Chief. You may also apply to be an Associate Editor-In-Chief of one of the subtopics below. Please mail us [2] to indicate your interest in serving either as an Editor-In-Chief of the entire topic or as an Associate Editor-In-Chief for a subtopic. Please be sure to attach your CV and or biographical sketch.
Overview
Glucagon-like peptide-1 analogs are a new class of drug for treatment of type 2 diabetes. [1] One of their advantages is that they have a lower risk of causing hypoglycemia.
Licenced:
- exenatide (2005)
Under investigation:
- albiglutide
- taspoglutide
References
- ↑ http://www.medscape.com/viewarticle/578304 "Glucagon-like Peptide-1 Analogs Other Than Exenatide"